👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

Both reported genotypes are homozygous, one in a consanguineous kindred. Heterozygous carriers are unaffected.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:30143481 SUPPORT Human Clinical

"She is homozygous for a loss-of-function IRF9 allele."

Establishes the homozygous loss-of-function genotype in the index patient, consistent with autosomal recessive inheritance.

?

Discussions and Knowledge Gaps

2

Why is type II interferon signalling intact in human IRF9 deficiency but impaired in the p48-null mouse, and does that divergence limit what the mouse can say about the human disease?

HUMAN MODEL MISMATCH irf9_mouse_type_ii_ifn_divergence

Attached to

pathophysiology#Failure of ISGF3 Trimer Assembly

The selectivity of the human defect is this entry's defining claim: patient cells form STAT1 homodimers normally, so the gamma-activated factor arm that transduces type II interferon still works, and the disease is an ISGF3 failure rather than a global interferon unresponsiveness. The p48-null mouse does not reproduce that boundary - in the mouse, the antiviral state induced by IFN-gamma is impaired too. Whether this reflects a species difference in how much type II interferon signalling depends on p48, a difference between a constitutive germline null and a hypomorphic human allele, or the difference between embryonic fibroblasts and the patient cell types assayed, is not resolved. Until it is, the mouse supports the ISG-induction node and cannot be used to argue about the selectivity.

Proposed experiments

GAF formation and IFN-gamma-induced antiviral state in p48-null mouse and IRF9-null human cells, matched by cell type

irf9_gaf_formation_across_species_and_cell_types

Assay STAT1 homodimer formation and the IFN-gamma-induced antiviral state side by side in p48-null mouse embryonic fibroblasts, p48-null mouse cells of a type matched to those assayed in patients, and IRF9-deficient human fibroblasts. The three-way comparison separates the candidate explanations the rationale names: if the mouse defect persists across cell types while the human one does not, it is a species difference; if it tracks cell type, the original discrepancy is an artefact of comparing embryonic fibroblasts with patient cells.

Would support

pathophysiology#Failure of ISGF3 Trimer Assembly

Supporting outcome

GAF formation and the IFN-gamma-induced antiviral state are intact in IRF9-null human cells but impaired in p48-null mouse cells of the same type, establishing a genuine species difference and confirming that the mouse cannot speak to the selectivity of the human defect.

Refuting outcome

The type II interferon defect in p48-null mouse cells disappears when a cell type matching the human assays is used, indicating the divergence is a comparison artefact rather than a species difference, and that the model may after all be informative about selectivity.

Show evidence (2 references)

PMID:9078371 SUPPORT Model Organism

"We show that p48 plays an essential role in both type I and type II IFN responses"

The mouse half of the mismatch: p48 is required for both interferon responses in the mouse.

PMID:30143481 SUPPORT In Vitro

"Her cells activate gamma-activated factor (GAF) STAT1 homodimers but not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in response to IFN-α2b."

The human half: GAF, the type II interferon transducer, forms normally in the patient's cells.

Does the type III interferon arm of the ISGF3 defect contribute independently to the IMD65 phenotype, or is the clinical disease entirely attributable to loss of type I interferon signalling?

KNOWLEDGE GAP irf9_type_iii_ifn_contribution

Attached to

pathophysiology#Failure of ISGF3 Trimer Assembly

IRF9 loss disables ISGF3 downstream of both the type I and the type III interferon receptor, and the founding paper's conclusion names both pathways. But patients whose cells cannot respond to type III interferons because of inherited IL10RB deficiency have no overt viral disease, which argues that the type III arm is largely redundant in humans and that the IMD65 phenotype is driven by the type I loss. The entry therefore does not model a separate type III node, and this discussion records why that absence is a judgement rather than an oversight.

Show evidence (2 references)

PMID:38781720 SUPPORT Human Clinical

"Patients with cells that do not respond to type III IFNs due to inherited IL10RB deficiency display no overt viral disease"

The observation that motivates the gap: an isolated type III unresponsiveness produces no viral phenotype, so the type III component of the ISGF3 defect cannot be assumed to contribute.

PMID:38781720 SUPPORT Other

"Current findings thus suggest that type III IFNs are largely redundant in humans. The essential functions of human type III IFNs, particularly in antiviral defenses, remain to be discovered."

States both the redundancy conclusion and that the question remains open, which is exactly the shape of this knowledge gap. Graded OTHER rather than HUMAN_CLINICAL because this sentence is the review's own synthesis across many patient series, not an observation from one.

⚙

Pathophysiology

8

Biallelic IRF9 Loss of Function

Homozygous or compound heterozygous loss-of-function variants in IRF9 abolish functional IRF9 protein. IRF9 is the DNA-binding component of ISGF3 and is not shared with any other interferon-responsive complex, so its loss removes exactly one signalling arm rather than degrading interferon signalling generally.

IRF9 hgnc:6131

Genetic context variant_origin: GERMLINE zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Downstream

Failure of ISGF3 Trimer Assembly

Show evidence (1 reference)

PMID:30143481 SUPPORT Human Clinical

"We report a 5-yr-old child with severe pulmonary influenza at 2 yr. She is homozygous for a loss-of-function IRF9 allele."

The founding case report establishing biallelic IRF9 loss of function as the cause of this disease.

Failure of ISGF3 Trimer Assembly

Without IRF9 the STAT1/STAT2/IRF9 trimer cannot form in response to type I interferon, while STAT1 homodimers (gamma-activated factor, GAF) still assemble normally. This is the discriminating molecular finding on functional testing and the reason the immunodeficiency is selective: the type II interferon arm, which signals through GAF, is intact.

ISGF3 complex GO:0070721

type I interferon-mediated signaling pathway GO:0060337 ↓ DECREASED

Downstream

Narrowed Interferon-Stimulated Gene Induction

Failure of USP18 Negative Feedback on Interferon Receptor Signalling

Show evidence (1 reference)

PMID:30143481 SUPPORT In Vitro

"Her cells activate gamma-activated factor (GAF) STAT1 homodimers but not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in response to IFN-α2b."

States precisely the selective defect this node models: GAF forms, ISGF3 does not. Graded IN_VITRO because the complex-formation assay was performed on the patient's cells.

Narrowed Interferon-Stimulated Gene Induction

The transcriptional response to type I interferon is much narrower than normal, though not absent - a residual subset of interferon-stimulated gene transcripts is still induced. That residue matters clinically: it is the most plausible reason the patient controls many common viruses normally and fails only against particular ones, and it is why this entry does not model the defect as an all-or-nothing loss of antiviral immunity.

response to type I interferon GO:0034340 ↓ DECREASED

Animal models

p48 (Irf9) knockout mouse Mouse partially recapitulates Interferon-inducible gene activation and establishment of the antiviral state are severely impaired, and ISRE-binding activity is absent in p48-null embryonic fibroblasts.

Downstream

Uncontrolled Replication of Respiratory Viruses

Show evidence (1 reference)

PMID:30143481 SUPPORT In Vitro

"The transcriptome induced by IFN-α2b in the patient's cells is much narrower than that of control cells; however, induction of a subset of IFN-stimulated gene transcripts remains detectable."

Supports both halves of this node: the transcriptional response is narrowed, and a residual subset survives. The second clause is what the node's clinical interpretation rests on.

Uncontrolled Replication of Respiratory Viruses

Patient cells fail to restrict influenza A virus, parainfluenza virus and respiratory syncytial virus in vitro, and the defect is rescued by wild-type IRF9 while silencing IRF9 in control cells reproduces it. That reciprocal experiment is what makes this a causal claim rather than an association.

defense response to virus GO:0051607 ↓ DECREASED

Downstream

Severe Viral Pneumonitis

Show evidence (1 reference)

PMID:30143481 SUPPORT In Vitro

"In vitro, the patient's cells do not control three respiratory viruses, influenza A virus (IAV), parainfluenza virus (PIV), and respiratory syncytial virus (RSV). These phenotypes are rescued by wild-type IRF9, whereas silencing IRF9 expression in control cells increases viral replication."

Reports both the failure of viral control and the rescue-and-knockdown pair that establishes IRF9 as the responsible factor.

Severe Viral Pneumonitis

The clinical endpoint of the antiviral arm: severe, sometimes life-threatening lower respiratory tract viral disease, presenting in the index patient as influenza A pneumonitis at two years of age. Notably the same child controlled respiratory viruses other than influenza A in vivo, so the in-vitro failure against PIV and RSV did not translate into clinical disease from those agents.

Downstream

Severe Viral Pneumonia

Show evidence (1 reference)

PMID:30143481 SUPPORT Human Clinical

"However, the child has controlled various common viruses in vivo, including respiratory viruses other than IAV. Our findings show that human IRF9- and ISGF3-dependent type I and III IFN responsive pathways are essential for controlling IAV."

Records the in-vivo/in-vitro discordance this node describes, and the authors' narrower conclusion that the pathway is essential specifically for influenza A control.

Failure of USP18 Negative Feedback on Interferon Receptor Signalling

ISGF3 loss suppresses but does not abrogate type I interferon receptor signalling. Because USP18 and other negative regulators are themselves ISGF3-induced, their induction fails and receptor signalling becomes abnormally prolonged. This is the mechanistic bridge to the inflammatory arm and resolves what otherwise looks like a contradiction - a patient who cannot mount an interferon response yet suffers interferon-driven inflammation.

negative regulation of type I interferon-mediated signaling pathway GO:0060339 ↓ DECREASED type I interferon-mediated signaling pathway GO:0060337 ↑ INCREASED

Downstream

Interferon-Gamma-Like Late Transcriptional Output

Show evidence (1 reference)

PMID:35182547 SUPPORT In Vitro

"Deficiency of any IFN-stimulated gene factor 3 component suppressed but did not abrogate IFN-I receptor signaling, which was abnormally prolonged, in keeping with insufficient induction of negative regulators such as ubiquitin-specific peptidase 18 (USP18)."

The direct statement of this node: signalling is suppressed but prolonged, and the reason is failed induction of USP18. Graded IN_VITRO because the kinetics were measured in patient primary cells and gene-edited iPSC-derived macrophages.

Interferon-Gamma-Like Late Transcriptional Output

In IRF9- or STAT2-deficient cells the late transcriptional response to type I interferon comes to mimic the effect of interferon-gamma. This is a measured cellular switch, kept separate from the clinical syndrome downstream so that the hedge in the literature sits on the edge it actually qualifies rather than on the observation itself.

type I interferon-mediated signaling pathway GO:0060337 ↑ INCREASED

Downstream

Hyperinflammation and Haemophagocytic Lymphohistiocytosis

Show evidence (1 reference)

PMID:35182547 SUPPORT In Vitro

"In cells lacking either STAT2 or IRF9, this late transcriptional response to IFN-α2b mimicked the effect of IFN-γ."

The measured transcriptional switch this node models, stated without hedging because the measurement itself is not hedged.

Hyperinflammation and Haemophagocytic Lymphohistiocytosis

The clinical inflammatory syndrome accompanying virus susceptibility. Modelled downstream of the transcriptional switch rather than bundled with it, because the causal link between the two is proposed rather than demonstrated - and that is a claim about this edge, not about either node.

inflammatory response GO:0006954 ↑ INCREASED

Downstream

Haemophagocytosis and Hyperinflammation

Show evidence (2 references)

PMID:35182547 SUPPORT In Vitro

"Aberrant IFN-α receptor signaling in STAT2- and IRF9-deficient cells switches the transcriptional output to a prolonged, IFN-γ-like response and likely contributes to clinically overt inflammation in these individuals."

Graded PARTIAL because the authors write "likely contributes". Now that the transcriptional switch and the clinical syndrome are separate nodes, this hedge attaches to the edge between them, which is the claim that is actually uncertain.

PMID:35182547 SUPPORT Human Clinical

"Inflammatory phenomena such as hyperinflammation or hemophagocytic lymphohistiocytosis are a frequent yet paradoxical accompaniment to virus susceptibility in patients with impairment of type I interferon (IFN-I) signaling caused by deficiency of signal transducer and activator of transcription..."

Establishes that the syndrome itself occurs in these patients, which is not hedged; only its attribution to the transcriptional switch is.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

2

Immune 1

Severe Viral Pneumonia HP:0002090

Severity: SEVERE

Show evidence (1 reference)

PMID:30143481 SUPPORT Human Clinical

"We report a 5-yr-old child with severe pulmonary influenza at 2 yr."

The presenting phenotype in the index patient. No frequency is recorded because the published cohort is a handful of kindreds.

Other 1

Haemophagocytosis and Hyperinflammation Hemophagocytosis HP:0012156

Show evidence (1 reference)

PMID:35182547 SUPPORT Human Clinical

"Inflammatory phenomena such as hyperinflammation or hemophagocytic lymphohistiocytosis are a frequent yet paradoxical accompaniment to virus susceptibility in patients with impairment of type I interferon (IFN-I) signaling caused by deficiency of signal transducer and activator of transcription..."

States that the inflammatory phenotype accompanies virus susceptibility in IRF9 deficiency. Note the sentence groups IRF9 with STAT2, so it is evidence for the class rather than for IRF9 alone.

🧬

Genetic Associations

1

IRF9

Gene: IRF9 hgnc:6131 relationship_type: CAUSATIVE

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:30143481 SUPPORT Human Clinical

"Our findings show that human IRF9- and ISGF3-dependent type I and III IFN responsive pathways are essential for controlling IAV."

The authors' causal conclusion linking IRF9 loss to the failure of antiviral control that defines this disease.

Variants (1)

c.991G>A Pathogenic

Homozygous in the index patient. Alters the last nucleotide of exon 7 and abolishes ISGF3 activation and ISGF3-dependent interferon stimulated gene induction on stimulation with IFN-alpha2.

Show evidence (1 reference)

PMID:34702736 SUPPORT Human Clinical

"We showed that the c.991G > A mutant IRF9 allele in the patient was loss-of-function, resulting in a lack of both ISGF-3 activation and ISGF-3–dependent IFN stimulated gene (ISG) induction following the stimulation of the patient's cells with IFN-α2"

Names the variant and states its loss-of-function consequence at both the complex-assembly and gene-induction levels.

💊

Medical Actions

2

Monoclonal Antibody Neutralization of SARS-CoV-2

Action: Pharmacotherapy NCIT:C15986

Agent: monoclonal antibody NCIT:C20401

Casirivimab and imdevimab given to the IRF9-deficient index patient on day 2 of symptomatic SARS-CoV-2 infection, with viraemia and clinical manifestations resolving by days 3 and 4. This is the one published treatment success specific to this genotype, and it is mechanistically the point of the entry: passive antibody neutralisation works precisely because it bypasses ISGF3 entirely, in a patient for whom interferon therapy was predicted to fail.

Mechanism Target:

Uncontrolled Replication of Respiratory Viruses — Acts on viral replication directly rather than on any node upstream of it, which is why it works in a patient whose interferon response cannot be restored.

Show evidence (2 references)

PMID:34702736 SUPPORT Human Clinical

"She was viremic on day 2 and received casirivimab and imdevimab. Her clinical manifestations and viremia disappeared on days 3 and 4, respectively."

The treatment and its observed effect in the index patient. This is a single case, which is why no efficacy claim beyond this patient is made.

PMID:34702736 SUPPORT Human Clinical

"Antibody-mediated SARS-CoV-2 neutralization is, therefore, sufficient to overcome a deficiency of antiviral IFNs."

The authors' mechanistic conclusion, which is what makes this treatment informative about the disease rather than only about the patient.

Prophylactic Immunoglobulin Replacement

Action: intravenous immunoglobulin therapy Ontology label: Intravenous Immunoglobulin Therapy NCIT:C121331

Intravenous immunoglobulin every three weeks, given to the index patient since her influenza episode. Reported alongside annual influenza vaccination as having considerably improved her clinical status, with no further severe viral illness. The two interventions were given together, so neither can be credited alone.

Mechanism Target:

Uncontrolled Replication of Respiratory Viruses — Supplies neutralising antibody from interferon-competent donors, acting downstream of the signalling defect rather than correcting it.

Show evidence (1 reference)

PMID:34702736 SUPPORT Human Clinical

"She has since received prophylactic intravenous IgG every 3 wk and has been vaccinated annually against influenza, which has considerably improved her clinical status, as she has developed no other severe viral illness."

Graded PARTIAL because the sentence attributes the improvement to immunoglobulin and annual influenza vaccination together. Reading it as support for immunoglobulin alone would be attributing a combined outcome to one arm of it, in a single patient.

🔬

Diagnosis

1

ISGF3 versus GAF Complex Formation Assay

The confirmatory functional test, and the one that discriminates IRF9 deficiency from a general interferon-signalling defect: patient cells fail to form ISGF3 trimers in response to type I interferon while forming STAT1 homodimers (GAF) normally. A defect that abolished both would point elsewhere in the pathway.

Show evidence (1 reference)

PMID:30143481 SUPPORT In Vitro

"Her cells activate gamma-activated factor (GAF) STAT1 homodimers but not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in response to IFN-α2b."

The discriminating result itself, which is what makes this a diagnostic test rather than a research observation.

📊

Prevalence

1

Worldwide

Cases In Literature Not yet documented

No prevalence estimate exists. IMD65 has been reported in a small number of kindreds, and this record exists to make that denominator structured rather than leaving it only in the entry's top-level notes. It should not be read as an estimate of zero.

🐁

Animal Models

1

p48 (Irf9) knockout mouse

Germline gene-targeted deletion of p48, the mouse IRF9 orthologue. Establishes the non-redundancy of the factor, but diverges from the human disease in a way that matters for how the entry can use it.

Species

Mouse

Genotype

p48 (Irf9) homozygous null by gene targeting

Publication

PMID:9078371

Pathograph links

Narrowed Interferon-Stimulated Gene Induction partially recapitulates fidelity: moderate Interferon-inducible gene activation and establishment of the antiviral state are severely impaired, and ISRE-binding activity is absent in p48-null embryonic fibroblasts.

Limitations: The mouse phenotype is broader than the human one. In p48-null mice the antiviral state is impaired in response to IFN-gamma as well as IFN-alpha, whereas the human disease is a selective ISGF3 defect with GAF-dependent type II interferon signalling intact. The model therefore overstates the breadth of the human lesion, and should not be cited for the selectivity that this entry treats as definitional.

Readouts

ISRE-binding activity in embryonic fibroblasts

Direction: ABOLISHED

Interpretation: Direct measure of the DNA-binding step that ISGF3 performs and that IRF9 is required for.

Show evidence (1 reference)

PMID:9078371 SUPPORT Model Organism

"activation of IFN-inducible genes and establishment of the antiviral state by IFN-alpha or -gamma are both severely impaired, and ISRE-binding activities induced by both IFNs are absent in the p48-negative embryonic fibroblasts (EFs)"

Reports the abolished ISRE binding and impaired antiviral state. The same sentence is also the source of the limitation recorded on this link, since it names IFN-gamma alongside IFN-alpha.

Show evidence (1 reference)

PMID:9078371 SUPPORT Model Organism

"We show that p48 plays an essential role in both type I and type II IFN responses"

Supports treating the model as informative for the ISG-induction node, and simultaneously states the divergence from human biology that the limitations field records.

{ }

Source YAML

click to show

name: Immunodeficiency 65 (IRF9 Deficiency)
creation_date: "2026-08-27T23:45:00Z"
category: Mendelian
description: >-
  Immunodeficiency 65 is an autosomal recessive inborn error of immunity caused
  by biallelic loss-of-function variants in IRF9, the DNA-binding subunit of the
  interferon-stimulated gene factor 3 (ISGF3) transcription factor complex. Type
  I and type III interferons signal through ISGF3, a trimer of STAT1, STAT2 and
  IRF9; without IRF9 the trimer cannot assemble, and the transcriptional
  programme those interferons induce collapses to a narrow residual subset. The
  clinical consequence is severe, sometimes life-threatening viral disease -
  influenza A pneumonitis in the index patient - against a background in which
  many other common viruses are still controlled. The defect is narrower than "no
  interferon response": STAT1 homodimers, the gamma-activated factor that
  transduces type II interferon, still form normally, so the disease is a
  selective failure of the ISGF3 arm rather than a global interferon
  unresponsiveness. A second, initially paradoxical arm of the phenotype is
  hyperinflammation and haemophagocytic lymphohistiocytosis. This is not a
  separate coincidence: ISGF3 loss suppresses but does not abolish signalling
  through the type I interferon receptor, and because it also fails to induce
  the negative regulator USP18, receptor signalling runs abnormally long and its
  late transcriptional output comes to resemble an interferon-gamma response.
  The same lesion therefore produces both too little antiviral defence and too
  much inflammation.
parents:
  - Inborn Error of Immunity
synonyms:
  - IMD65
  - IRF9 deficiency
  - ISGF3-gamma deficiency
  - p48 deficiency
disease_term:
  preferred_term: immunodeficiency 65, susceptibility to viral infections
  term:
    id: MONDO:0032848
    label: immunodeficiency 65, susceptibility to viral infections
notes: >-
  Evidence-base caveat, stated up front because it governs how every frequency
  and phenotype claim in this entry should be read. IMD65 has been reported in
  only a small number of kindreds. Per-phenotype frequencies cannot be computed
  from that denominator, so this entry deliberately carries no frequency values
  on its phenotypes rather than converting single-family observations into
  FrequencyEnum bands. Where a claim rests on one patient, the evidence
  explanation says so.

  Relationship to STAT2_Deficiency. kb/disorders/STAT2_Deficiency.yaml curates
  the sibling defect in the same ISGF3 complex. The two entries share the
  prolonged-IFNAR-signalling mechanism and cite the same source for it
  (PMID:35182547, which studied STAT1-, STAT2- and IRF9-deficient cells side by
  side). They are kept as separate entries because the causal gene differs; the
  shared node is stated in both rather than cross-referenced, following the
  project's non-DRY convention for conserved mechanisms.
inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      Both reported genotypes are homozygous, one in a consanguineous kindred.
      Heterozygous carriers are unaffected.
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          She is homozygous for a loss-of-function IRF9 allele.
        explanation: >-
          Establishes the homozygous loss-of-function genotype in the index
          patient, consistent with autosomal recessive inheritance.
pathophysiology:
  - name: Biallelic IRF9 Loss of Function
    biological_scale: MOLECULAR
    description: >-
      Homozygous or compound heterozygous loss-of-function variants in IRF9
      abolish functional IRF9 protein. IRF9 is the DNA-binding component of
      ISGF3 and is not shared with any other interferon-responsive complex, so
      its loss removes exactly one signalling arm rather than degrading
      interferon signalling generally.
    genes:
      - preferred_term: IRF9
        term:
          id: hgnc:6131
          label: IRF9
    genetic_context:
      functional_impact_category: LOSS_OF_FUNCTION
      zygosity: HOMOZYGOUS
      variant_origin: GERMLINE
    downstream:
      - target: Failure of ISGF3 Trimer Assembly
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We report a 5-yr-old child with severe pulmonary influenza at 2 yr.
          She is homozygous for a loss-of-function IRF9 allele.
        explanation: >-
          The founding case report establishing biallelic IRF9 loss of function
          as the cause of this disease.
  - name: Failure of ISGF3 Trimer Assembly
    biological_scale: MOLECULAR
    description: >-
      Without IRF9 the STAT1/STAT2/IRF9 trimer cannot form in response to type I
      interferon, while STAT1 homodimers (gamma-activated factor, GAF) still
      assemble normally. This is the discriminating molecular finding on
      functional testing and the reason the immunodeficiency is selective: the
      type II interferon arm, which signals through GAF, is intact.
    protein_complexes:
      - preferred_term: ISGF3 complex
        term:
          id: GO:0070721
          label: ISGF3 complex
        modifier: DECREASED
    biological_processes:
      - preferred_term: type I interferon-mediated signaling pathway
        term:
          id: GO:0060337
          label: type I interferon-mediated signaling pathway
        modifier: DECREASED
    downstream:
      - target: Narrowed Interferon-Stimulated Gene Induction
      - target: Failure of USP18 Negative Feedback on Interferon Receptor Signalling
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Her cells activate gamma-activated factor (GAF) STAT1 homodimers but
          not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in
          response to IFN-α2b.
        explanation: >-
          States precisely the selective defect this node models: GAF forms,
          ISGF3 does not. Graded IN_VITRO because the complex-formation assay
          was performed on the patient's cells.
  - name: Narrowed Interferon-Stimulated Gene Induction
    biological_scale: CELLULAR
    description: >-
      The transcriptional response to type I interferon is much narrower than
      normal, though not absent - a residual subset of interferon-stimulated
      gene transcripts is still induced. That residue matters clinically: it is
      the most plausible reason the patient controls many common viruses
      normally and fails only against particular ones, and it is why this entry
      does not model the defect as an all-or-nothing loss of antiviral immunity.
    biological_processes:
      - preferred_term: response to type I interferon
        term:
          id: GO:0034340
          label: response to type I interferon
        modifier: DECREASED
    downstream:
      - target: Uncontrolled Replication of Respiratory Viruses
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The transcriptome induced by IFN-α2b in the patient's cells is much
          narrower than that of control cells; however, induction of a subset of
          IFN-stimulated gene transcripts remains detectable.
        explanation: >-
          Supports both halves of this node: the transcriptional response is
          narrowed, and a residual subset survives. The second clause is what
          the node's clinical interpretation rests on.
  - name: Uncontrolled Replication of Respiratory Viruses
    biological_scale: CELLULAR
    description: >-
      Patient cells fail to restrict influenza A virus, parainfluenza virus and
      respiratory syncytial virus in vitro, and the defect is rescued by
      wild-type IRF9 while silencing IRF9 in control cells reproduces it. That
      reciprocal experiment is what makes this a causal claim rather than an
      association.
    biological_processes:
      - preferred_term: defense response to virus
        term:
          id: GO:0051607
          label: defense response to virus
        modifier: DECREASED
    downstream:
      - target: Severe Viral Pneumonitis
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          In vitro, the patient's cells do not control three respiratory
          viruses, influenza A virus (IAV), parainfluenza virus (PIV), and
          respiratory syncytial virus (RSV). These phenotypes are rescued by
          wild-type IRF9, whereas silencing IRF9 expression in control cells
          increases viral replication.
        explanation: >-
          Reports both the failure of viral control and the rescue-and-knockdown
          pair that establishes IRF9 as the responsible factor.
  - name: Severe Viral Pneumonitis
    biological_scale: ORGANISM
    description: >-
      The clinical endpoint of the antiviral arm: severe, sometimes
      life-threatening lower respiratory tract viral disease, presenting in the
      index patient as influenza A pneumonitis at two years of age. Notably the
      same child controlled respiratory viruses other than influenza A in vivo,
      so the in-vitro failure against PIV and RSV did not translate into
      clinical disease from those agents.
    downstream:
      - target: Severe Viral Pneumonia
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          However, the child has controlled various common viruses in vivo,
          including respiratory viruses other than IAV. Our findings show that
          human IRF9- and ISGF3-dependent type I and III IFN responsive pathways
          are essential for controlling IAV.
        explanation: >-
          Records the in-vivo/in-vitro discordance this node describes, and the
          authors' narrower conclusion that the pathway is essential
          specifically for influenza A control.
  - name: Failure of USP18 Negative Feedback on Interferon Receptor Signalling
    biological_scale: CELLULAR
    description: >-
      ISGF3 loss suppresses but does not abrogate type I interferon receptor
      signalling. Because USP18 and other negative regulators are themselves
      ISGF3-induced, their induction fails and receptor signalling becomes
      abnormally prolonged. This is the mechanistic bridge to the inflammatory
      arm and resolves what otherwise looks like a contradiction - a patient who
      cannot mount an interferon response yet suffers interferon-driven
      inflammation.
    biological_processes:
      - preferred_term: negative regulation of type I interferon-mediated signaling pathway
        term:
          id: GO:0060339
          label: negative regulation of type I interferon-mediated signaling pathway
        modifier: DECREASED
      - preferred_term: type I interferon-mediated signaling pathway
        term:
          id: GO:0060337
          label: type I interferon-mediated signaling pathway
        modifier: INCREASED
    downstream:
      - target: Interferon-Gamma-Like Late Transcriptional Output
    notes: >-
      The two process terms here say different things and are not in tension.
      GO:0060339 DECREASED is the substantive claim - the brake fails, because
      USP18 and the other negative regulators are themselves ISGF3-induced.
      GO:0060337 INCREASED records the consequence, that receptor-proximal
      signalling therefore runs long. Binding the negative-regulation term
      directly is what makes this coherent with the DECREASED modifier on
      GO:0060337 at the ISGF3 assembly node, where the claim is about
      ISGF3-dependent transcription rather than about signalling duration.
    evidence:
      - reference: PMID:35182547
        reference_title: "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Deficiency of any IFN-stimulated gene factor 3 component suppressed
          but did not abrogate IFN-I receptor signaling, which was abnormally
          prolonged, in keeping with insufficient induction of negative
          regulators such as ubiquitin-specific peptidase 18 (USP18).
        explanation: >-
          The direct statement of this node: signalling is suppressed but
          prolonged, and the reason is failed induction of USP18. Graded
          IN_VITRO because the kinetics were measured in patient primary cells
          and gene-edited iPSC-derived macrophages.
  - name: Interferon-Gamma-Like Late Transcriptional Output
    biological_scale: CELLULAR
    description: >-
      In IRF9- or STAT2-deficient cells the late transcriptional response to
      type I interferon comes to mimic the effect of interferon-gamma. This is a
      measured cellular switch, kept separate from the clinical syndrome
      downstream so that the hedge in the literature sits on the edge it
      actually qualifies rather than on the observation itself.
    biological_processes:
      - preferred_term: type I interferon-mediated signaling pathway
        term:
          id: GO:0060337
          label: type I interferon-mediated signaling pathway
        modifier: INCREASED
    downstream:
      - target: Hyperinflammation and Haemophagocytic Lymphohistiocytosis
    evidence:
      - reference: PMID:35182547
        reference_title: "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          In cells lacking either STAT2 or IRF9, this late transcriptional
          response to IFN-α2b mimicked the effect of IFN-γ.
        explanation: >-
          The measured transcriptional switch this node models, stated without
          hedging because the measurement itself is not hedged.
  - name: Hyperinflammation and Haemophagocytic Lymphohistiocytosis
    biological_scale: ORGANISM
    description: >-
      The clinical inflammatory syndrome accompanying virus susceptibility.
      Modelled downstream of the transcriptional switch rather than bundled with
      it, because the causal link between the two is proposed rather than
      demonstrated - and that is a claim about this edge, not about either node.
    biological_processes:
      - preferred_term: inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
        modifier: INCREASED
    downstream:
      - target: Haemophagocytosis and Hyperinflammation
    evidence:
      - reference: PMID:35182547
        reference_title: "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Aberrant IFN-α receptor signaling in STAT2- and IRF9-deficient cells
          switches the transcriptional output to a prolonged, IFN-γ-like
          response and likely contributes to clinically overt inflammation in
          these individuals.
        explanation: >-
          Graded PARTIAL because the authors write "likely contributes". Now
          that the transcriptional switch and the clinical syndrome are separate
          nodes, this hedge attaches to the edge between them, which is the
          claim that is actually uncertain.
      - reference: PMID:35182547
        reference_title: "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Inflammatory phenomena such as hyperinflammation or hemophagocytic
          lymphohistiocytosis are a frequent yet paradoxical accompaniment to
          virus susceptibility in patients with impairment of type I interferon
          (IFN-I) signaling caused by deficiency of signal transducer and
          activator of transcription 2 (STAT2) or IFN regulatory factor 9
          (IRF9).
        explanation: >-
          Establishes that the syndrome itself occurs in these patients, which
          is not hedged; only its attribution to the transcriptional switch is.
phenotypes:
  - name: Severe Viral Pneumonia
    category: Respiratory
    description: >-
      Life-threatening lower respiratory tract viral infection, presenting in
      the index patient as influenza A pneumonitis at two years of age requiring
      intensive care.
    phenotype_term:
      preferred_term: Pneumonia
      term:
        id: HP:0002090
        label: Pneumonia
      severity: SEVERE
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We report a 5-yr-old child with severe pulmonary influenza at 2 yr.
        explanation: >-
          The presenting phenotype in the index patient. No frequency is
          recorded because the published cohort is a handful of kindreds.
  - name: Haemophagocytosis and Hyperinflammation
    category: Hematologic
    description: >-
      Hyperinflammation and haemophagocytic lymphohistiocytosis occur alongside
      virus susceptibility. Described as a frequent accompaniment in patients
      with impaired type I interferon signalling from STAT2 or IRF9 deficiency.
    phenotype_term:
      preferred_term: Hemophagocytosis
      term:
        id: HP:0012156
        label: Hemophagocytosis
    evidence:
      - reference: PMID:35182547
        reference_title: "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Inflammatory phenomena such as hyperinflammation or hemophagocytic
          lymphohistiocytosis are a frequent yet paradoxical accompaniment to
          virus susceptibility in patients with impairment of type I interferon
          (IFN-I) signaling caused by deficiency of signal transducer and
          activator of transcription 2 (STAT2) or IFN regulatory factor 9
          (IRF9).
        explanation: >-
          States that the inflammatory phenotype accompanies virus
          susceptibility in IRF9 deficiency. Note the sentence groups IRF9 with
          STAT2, so it is evidence for the class rather than for IRF9 alone.
genetic:
  - name: IRF9
    relationship_type: CAUSATIVE
    gene_term:
      preferred_term: IRF9
      term:
        id: hgnc:6131
        label: IRF9
    notes: >-
      Gene identity is worth recording explicitly here. The deep-research report
      used to curate this entry gave the gene as HGNC:6398; that CURIE is KPNA5.
      IRF9 is hgnc:6131, which is also what the curation stub carried, and this
      entry uses the verified identifier.

      Two loss-of-function alleles are reported, both homozygous. The index
      patient carries c.991G>A, which alters the last nucleotide of exon 7; the
      second kindred, consanguineous, carries the splice-donor variant
      c.577+1G>T, causing exon 5 skipping and a premature stop. Only the first
      is quotable from a cached abstract, so only it carries an evidence item
      below; the second is recorded here in prose rather than as an unsourced
      structured claim.
    inheritance:
      - name: Autosomal recessive inheritance
        inheritance_term:
          preferred_term: Autosomal recessive inheritance
          term:
            id: HP:0000007
            label: Autosomal recessive inheritance
    variants:
      - name: c.991G>A
        description: >-
          Homozygous in the index patient. Alters the last nucleotide of exon 7
          and abolishes ISGF3 activation and ISGF3-dependent interferon
          stimulated gene induction on stimulation with IFN-alpha2.
        clinical_significance: PATHOGENIC
        evidence:
          - reference: PMID:34702736
            reference_title: "Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              We showed that the c.991G > A mutant IRF9 allele in the patient
              was loss-of-function, resulting in a lack of both ISGF-3
              activation and ISGF-3–dependent IFN stimulated gene (ISG)
              induction following the stimulation of the patient's cells with
              IFN-α2
            explanation: >-
              Names the variant and states its loss-of-function consequence at
              both the complex-assembly and gene-induction levels.
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our findings show that human IRF9- and ISGF3-dependent type I and III
          IFN responsive pathways are essential for controlling IAV.
        explanation: >-
          The authors' causal conclusion linking IRF9 loss to the failure of
          antiviral control that defines this disease.
discussions:
  - discussion_id: irf9_mouse_type_ii_ifn_divergence
    kind: HUMAN_MODEL_MISMATCH
    prompt: >-
      Why is type II interferon signalling intact in human IRF9 deficiency but
      impaired in the p48-null mouse, and does that divergence limit what the
      mouse can say about the human disease?
    attaches_to:
      - pathophysiology#Failure of ISGF3 Trimer Assembly
    rationale: >-
      The selectivity of the human defect is this entry's defining claim:
      patient cells form STAT1 homodimers normally, so the gamma-activated
      factor arm that transduces type II interferon still works, and the disease
      is an ISGF3 failure rather than a global interferon unresponsiveness. The
      p48-null mouse does not reproduce that boundary - in the mouse, the
      antiviral state induced by IFN-gamma is impaired too. Whether this
      reflects a species difference in how much type II interferon signalling
      depends on p48, a difference between a constitutive germline null and a
      hypomorphic human allele, or the difference between embryonic fibroblasts
      and the patient cell types assayed, is not resolved. Until it is, the
      mouse supports the ISG-induction node and cannot be used to argue about
      the selectivity.
    proposed_experiments:
      - experiment_id: irf9_gaf_formation_across_species_and_cell_types
        name: >-
          GAF formation and IFN-gamma-induced antiviral state in p48-null mouse
          and IRF9-null human cells, matched by cell type
        description: >-
          Assay STAT1 homodimer formation and the IFN-gamma-induced antiviral
          state side by side in p48-null mouse embryonic fibroblasts, p48-null
          mouse cells of a type matched to those assayed in patients, and
          IRF9-deficient human fibroblasts. The three-way comparison separates
          the candidate explanations the rationale names: if the mouse defect
          persists across cell types while the human one does not, it is a
          species difference; if it tracks cell type, the original discrepancy
          is an artefact of comparing embryonic fibroblasts with patient cells.
        would_support:
          - pathophysiology#Failure of ISGF3 Trimer Assembly
        supporting_outcome:
          - >-
            GAF formation and the IFN-gamma-induced antiviral state are intact
            in IRF9-null human cells but impaired in p48-null mouse cells of the
            same type, establishing a genuine species difference and confirming
            that the mouse cannot speak to the selectivity of the human defect.
        refuting_outcome:
          - >-
            The type II interferon defect in p48-null mouse cells disappears
            when a cell type matching the human assays is used, indicating the
            divergence is a comparison artefact rather than a species
            difference, and that the model may after all be informative about
            selectivity.
    evidence:
      - reference: PMID:9078371
        reference_title: >-
          Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in
          both type I and type II interferon responses, as revealed by gene
          targeting studies.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          We show that p48 plays an essential role in both type I and type II
          IFN responses
        explanation: >-
          The mouse half of the mismatch: p48 is required for both interferon
          responses in the mouse.
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Her cells activate gamma-activated factor (GAF) STAT1 homodimers but
          not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in
          response to IFN-α2b.
        explanation: >-
          The human half: GAF, the type II interferon transducer, forms
          normally in the patient's cells.
  - discussion_id: irf9_type_iii_ifn_contribution
    kind: KNOWLEDGE_GAP
    prompt: >-
      Does the type III interferon arm of the ISGF3 defect contribute
      independently to the IMD65 phenotype, or is the clinical disease entirely
      attributable to loss of type I interferon signalling?
    attaches_to:
      - pathophysiology#Failure of ISGF3 Trimer Assembly
    rationale: >-
      IRF9 loss disables ISGF3 downstream of both the type I and the type III
      interferon receptor, and the founding paper's conclusion names both
      pathways. But patients whose cells cannot respond to type III interferons
      because of inherited IL10RB deficiency have no overt viral disease, which
      argues that the type III arm is largely redundant in humans and that the
      IMD65 phenotype is driven by the type I loss. The entry therefore does not
      model a separate type III node, and this discussion records why that
      absence is a judgement rather than an oversight.
    evidence:
      - reference: PMID:38781720
        reference_title: "In search of a function for human type III interferons: insights from inherited and acquired deficits."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Patients with cells that do not respond to type III IFNs due to
          inherited IL10RB deficiency display no overt viral disease
        explanation: >-
          The observation that motivates the gap: an isolated type III
          unresponsiveness produces no viral phenotype, so the type III
          component of the ISGF3 defect cannot be assumed to contribute.
      - reference: PMID:38781720
        reference_title: "In search of a function for human type III interferons: insights from inherited and acquired deficits."
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Current findings thus suggest that type III IFNs are largely redundant
          in humans. The essential functions of human type III IFNs,
          particularly in antiviral defenses, remain to be discovered.
        explanation: >-
          States both the redundancy conclusion and that the question remains
          open, which is exactly the shape of this knowledge gap. Graded OTHER
          rather than HUMAN_CLINICAL because this sentence is the review's own
          synthesis across many patient series, not an observation from one.
prevalence:
  - population: Worldwide
    measure_type: CASES_IN_LITERATURE
    prevalence_class: NOT_YET_DOCUMENTED
    notes: >-
      No prevalence estimate exists. IMD65 has been reported in a small number
      of kindreds, and this record exists to make that denominator structured
      rather than leaving it only in the entry's top-level notes. It should not
      be read as an estimate of zero.
treatments:
  - name: Monoclonal Antibody Neutralization of SARS-CoV-2
    description: >-
      Casirivimab and imdevimab given to the IRF9-deficient index patient on day
      2 of symptomatic SARS-CoV-2 infection, with viraemia and clinical
      manifestations resolving by days 3 and 4. This is the one published
      treatment success specific to this genotype, and it is mechanistically the
      point of the entry: passive antibody neutralisation works precisely
      because it bypasses ISGF3 entirely, in a patient for whom interferon
      therapy was predicted to fail.
    therapeutic_modality: MONOCLONAL_ANTIBODY
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: monoclonal antibody
          term:
            id: NCIT:C20401
            label: Monoclonal Antibody
    target_mechanisms:
      - target: Uncontrolled Replication of Respiratory Viruses
        description: >-
          Acts on viral replication directly rather than on any node upstream of
          it, which is why it works in a patient whose interferon response
          cannot be restored.
    evidence:
      - reference: PMID:34702736
        reference_title: "Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          She was viremic on day 2 and received casirivimab and imdevimab. Her
          clinical manifestations and viremia disappeared on days 3 and 4,
          respectively.
        explanation: >-
          The treatment and its observed effect in the index patient. This is a
          single case, which is why no efficacy claim beyond this patient is made.
      - reference: PMID:34702736
        reference_title: "Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Antibody-mediated SARS-CoV-2 neutralization is, therefore, sufficient
          to overcome a deficiency of antiviral IFNs.
        explanation: >-
          The authors' mechanistic conclusion, which is what makes this
          treatment informative about the disease rather than only about the
          patient.
  - name: Prophylactic Immunoglobulin Replacement
    description: >-
      Intravenous immunoglobulin every three weeks, given to the index patient
      since her influenza episode. Reported alongside annual influenza
      vaccination as having considerably improved her clinical status, with no
      further severe viral illness. The two interventions were given together,
      so neither can be credited alone.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: intravenous immunoglobulin therapy
      term:
        id: NCIT:C121331
        label: Intravenous Immunoglobulin Therapy
    target_mechanisms:
      - target: Uncontrolled Replication of Respiratory Viruses
        description: >-
          Supplies neutralising antibody from interferon-competent donors,
          acting downstream of the signalling defect rather than correcting it.
    evidence:
      - reference: PMID:34702736
        reference_title: "Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          She has since received prophylactic intravenous IgG every 3 wk and has
          been vaccinated annually against influenza, which has considerably
          improved her clinical status, as she has developed no other severe
          viral illness.
        explanation: >-
          Graded PARTIAL because the sentence attributes the improvement to
          immunoglobulin and annual influenza vaccination together. Reading it
          as support for immunoglobulin alone would be attributing a combined
          outcome to one arm of it, in a single patient.
diagnosis:
  - name: ISGF3 versus GAF Complex Formation Assay
    description: >-
      The confirmatory functional test, and the one that discriminates IRF9
      deficiency from a general interferon-signalling defect: patient cells fail
      to form ISGF3 trimers in response to type I interferon while forming STAT1
      homodimers (GAF) normally. A defect that abolished both would point
      elsewhere in the pathway.
    evidence:
      - reference: PMID:30143481
        reference_title: "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Her cells activate gamma-activated factor (GAF) STAT1 homodimers but
          not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/IRF9) in
          response to IFN-α2b.
        explanation: >-
          The discriminating result itself, which is what makes this a
          diagnostic test rather than a research observation.
animal_models:
  - name: p48 (Irf9) knockout mouse
    species: Mouse
    genotype: p48 (Irf9) homozygous null by gene targeting
    publication: PMID:9078371
    description: >-
      Germline gene-targeted deletion of p48, the mouse IRF9 orthologue.
      Establishes the non-redundancy of the factor, but diverges from the human
      disease in a way that matters for how the entry can use it.
    modeled_mechanisms:
      - target: Narrowed Interferon-Stimulated Gene Induction
        relationship: PARTIALLY_RECAPITULATES
        fidelity: MODERATE
        description: >-
          Interferon-inducible gene activation and establishment of the
          antiviral state are severely impaired, and ISRE-binding activity is
          absent in p48-null embryonic fibroblasts.
        limitations: >-
          The mouse phenotype is broader than the human one. In p48-null mice
          the antiviral state is impaired in response to IFN-gamma as well as
          IFN-alpha, whereas the human disease is a selective ISGF3 defect with
          GAF-dependent type II interferon signalling intact. The model
          therefore overstates the breadth of the human lesion, and should not
          be cited for the selectivity that this entry treats as definitional.
        readouts:
          - name: ISRE-binding activity in embryonic fibroblasts
            target: Narrowed Interferon-Stimulated Gene Induction
            direction: ABOLISHED
            interpretation: >-
              Direct measure of the DNA-binding step that ISGF3 performs and
              that IRF9 is required for.
            evidence:
              - reference: PMID:9078371
                reference_title: >-
                  Essential and non-redundant roles of p48 (ISGF3 gamma) and
                  IRF-1 in both type I and type II interferon responses, as
                  revealed by gene targeting studies.
                supports: SUPPORT
                evidence_source: MODEL_ORGANISM
                snippet: >-
                  activation of IFN-inducible genes and establishment of the
                  antiviral state by IFN-alpha or -gamma are both severely
                  impaired, and ISRE-binding activities induced by both IFNs are
                  absent in the p48-negative embryonic fibroblasts (EFs)
                explanation: >-
                  Reports the abolished ISRE binding and impaired antiviral
                  state. The same sentence is also the source of the limitation
                  recorded on this link, since it names IFN-gamma alongside
                  IFN-alpha.
        evidence:
          - reference: PMID:9078371
            reference_title: >-
              Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1
              in both type I and type II interferon responses, as revealed by
              gene targeting studies.
            supports: SUPPORT
            evidence_source: MODEL_ORGANISM
            snippet: >-
              We show that p48 plays an essential role in both type I and type
              II IFN responses
            explanation: >-
              Supports treating the model as informative for the ISG-induction
              node, and simultaneously states the divergence from human
              biology that the limitations field records.

📚

References & Deep Research

Deep Research

1

Claude Code ▸

Immunodeficiency 65 (IRF9 Deficiency): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 18 citations 2026-08-27T23:22:12.995495

Immunodeficiency 65 (IRF9 Deficiency): Comprehensive Research Report

1. Disease Information

Overview. Immunodeficiency 65 (IMD65), also called "IRF9 deficiency" or "primary immunodeficiency with predisposition to severe viral infection," is an autosomal recessive inborn error of immunity (IEI) caused by biallelic loss-of-function variants in IRF9. It disrupts the interferon-stimulated gene factor 3 (ISGF3) transcription-factor complex, crippling the cellular response to type I (IFN-α/β) and type III (IFN-λ) interferons and leaving affected children susceptible to severe, sometimes life-threatening, viral infections from early life (OMIM #618648) [omim.org/entry/618648].

Key identifiers: - OMIM disease: #618648 (IMMUNODEFICIENCY 65, SUSCEPTIBILITY TO VIRAL INFECTIONS; IMD65) - OMIM gene: 147574 (INTERFERON REGULATORY FACTOR 9; IRF9) - Gene location: Chromosome 14q12 (9 exons; exons 2–9 protein-coding) - Inheritance: Autosomal recessive - Related but distinct entries:* IMD51 (IRF7 deficiency, OMIM #613953) and IMD62 (STAT2 deficiency, OMIM #618459) — both also disrupt ISGF3-dependent signaling and share overlapping phenotypes.

Synonyms: IRF9 deficiency; ISGF3γ (p48) deficiency; primary immunodeficiency with predisposition to severe viral infection.

Data provenance. Clinical knowledge of IMD65 is derived almost entirely from individual patient case reports (at most two or three unrelated families/kindreds published to date), not from a large aggregated disease cohort — this is an ultra-rare monogenic IEI, and virtually every published clinical detail traces back to primary case reports from the Casanova/Zhang laboratories (Rockefeller/Imagine Institute) and UK/Newcastle groups studying inborn errors of type I IFN immunity.

Sources: OMIM #618648 · OMIM *147574 · GeneCards IRF9

2. Etiology

Disease-causal factor: Purely genetic — biallelic (homozygous or compound heterozygous) loss-of-function variants in IRF9 that abolish or severely impair ISGF3 complex assembly.

Genetic risk factors: - Homozygous or compound heterozygous null/hypomorphic IRF9 alleles. - Consanguinity is a recognized risk factor: the second reported family (two affected siblings) arose in a consanguineous kindred (identified through gene-panel sequencing) [Duncan/Bucciol et al., JACI 2022].

Reported causal variants: | Patient/family | Variant | Consequence | Zygosity | |---|---|---|---| | Index case (Hernandez et al. 2018, JEM) | c.991G>A (last nucleotide of exon 7), possible p.Asp331Asn | Predicted splice-site alteration ± missense | Homozygous | | Two siblings (Duncan et al. 2022, JACI) | c.577+1G>T | Splice-donor loss → exon 5 skipping → premature stop codon | Homozygous (consanguineous family) |

ClinVar entries document both variants under "Immunodeficiency 65, susceptibility to viral infections" (RCV000855434 for c.577+1G>T; RCV000855435 for c.991G>A / p.Asp331Asn).

Environmental/triggering factors are not causal but are disease-revealing: because the defect is in an antiviral pathway, the phenotype is essentially unmasked only upon viral challenge — influenza A virus, respiratory syncytial virus (RSV), parainfluenza virus, adenovirus, varicella-zoster virus (VZV, including vaccine-strain), HSV-1, and SARS-CoV-2 have all precipitated severe disease episodes in reported patients.

Protective factors: No genetic protective variants are described (the gene is essentially haploinsufficiency-tolerant but complete biallelic loss is deleterious). Prophylactic immunoglobulin (containing neutralizing antibodies from IFN-competent donors) and, in the COVID-19 case, exogenous SARS-CoV-2 neutralizing monoclonal antibodies were protective by bypassing the defective interferon-dependent antiviral pathway entirely (see Treatment).

Gene-environment interaction: The defect is a pure loss-of-function in the host antiviral signaling axis; interaction is essentially "genotype defines penetrance of specific viral phenotypes" — e.g., live-attenuated viral vaccines (yellow fever 17D, VZV, MMR) act as the "environmental trigger" that a competent ISGF3 pathway would normally control, but in IRF9-deficient individuals cause vaccine-strain disseminated disease.

Sources: Hernandez et al. 2018, JEM 215(10):2567–2585 · ClinVar RCV000855434 · ClinVar RCV000855435

3. Phenotypes

Reported phenotypes span three domains — infectious, vaccine-associated, and inflammatory/immune-dysregulation.

Infectious phenotypes

Phenotype	Onset	Severity/course	Suggested HPO term
Life-threatening influenza pneumonitis	Early childhood (age 2 in index case)	Severe, ICU/mechanical ventilation	HP:0011947 (Respiratory tract infection), consider HP:0002090 (Pneumonia)
Critical COVID-19 pneumonia risk	Any age	High viral load, viremia (documented Ct 16.5 nasal load)	HP:0002090
RSV, parainfluenza, adenovirus infections	Infancy	Recurrent, severe; "unrestricted viral replication" shown in vitro	HP:0011947
Recurrent bronchiolitis	Infancy	Recurrent	HP:0011950 (Bronchiolitis)
Bronchiectasis (sequela)	Later childhood	Progressive/structural lung damage	HP:0002110 (Bronchiectasis)
Disseminated post-vaccination VZV	Post-vaccination	Severe, pneumonitis; reported fatal outcome in some vaccine-related episodes	HP:0011971 (poor response to vaccination)
Fatal enterohemorrhagic/viscerotropic disease after yellow fever vaccination	Post-vaccination	Fatal in at least one reported case	related to HP:0011971
HSV-1 encephalitis susceptibility	Any age (class effect of ISGF3 deficiency)	Severe	HP:0002383 (Encephalitis)
Recurrent fevers of unknown cause	Childhood	Recurrent	HP:0001945 (Fever)
Sepsis/septic shock	Any age	Life-threatening	HP:0100806 (Shock)
Neurological sequelae (post-infectious)	Following severe infection episodes	Persistent	HP:0012759 (Neurodevelopmental abnormality)

Inflammatory/immune dysregulation phenotypes

Paradoxically, IRF9-deficient (and STAT2-deficient) patients show a propensity to hyperinflammation and hemophagocytic lymphohistiocytosis (HLH) despite failing to control viruses. Mechanistically, loss of ISGF3 does not eliminate all type I IFN receptor (IFNAR) signaling — it removes negative feedback (via reduced induction of USP18), causing abnormally prolonged IFNAR signaling that switches the transcriptional output toward a sustained, IFN-γ (GAF)-like inflammatory program, contributing to overt clinical inflammation [Duncan et al. 2022, JACI]. HPO term: HP:0005522/HP:0004315 (Hemophagocytic lymphohistiocytosis-related) — code HP:0005537 if modeling.

Laboratory abnormalities

Lymphopenia and/or hypogammaglobulinemia, particularly evident during acute infection (per OMIM clinical synopsis).
Impaired cellular type I interferon response (defective ISGF3 formation on functional testing; intact GAF/STAT1-homodimer formation).

Severity/progression: Onset is neonatal-to-early-infancy; course is episodic (severe infections punctuated by relative wellness) but can leave permanent sequelae (bronchiectasis, neurological impairment after severe CNS/systemic infection episodes). Frequency data (percentage of patients with each feature) cannot be meaningfully computed given the extremely small published cohort (2–3 kindreds).

Quality of life impact: Not formally studied with QoL instruments (no EQ-5D/SF-36 data identified); qualitatively, recurrent ICU admissions, bronchiectasis, and neurological impairment described in the second family imply substantial chronic morbidity.

Sources: Hernandez et al. 2018 JEM · Duncan et al. 2022 JACI (Aberrant inflammatory responses) · Vanderver et al./monoclonal antibody case, PMC8609338 · OMIM #618648 Clinical Synopsis

4. Genetic/Molecular Information

Causal gene: IRF9 (HGNC:6398; NCBI Gene ID 10379; OMIM *147574), encoding Interferon Regulatory Factor 9 (also historically named ISGF3γ or p48).

Reference transcript: NM_006084.5 (used in ClinVar variant nomenclature).

Pathogenic variants documented: 1. c.991G>A — last nucleotide of exon 7; predicted to cause a splice-site alteration and possibly p.Asp331Asn substitution. Homozygous in the index patient (Hernandez et al. 2018). 2. c.577+1G>T — canonical splice-donor site variant causing skipping of exon 5 and a premature stop codon (frameshift/truncation). Homozygous in two siblings from a consanguineous family (Duncan et al. 2022).

Variant classification: Both variants are classified as pathogenic/likely pathogenic for "Immunodeficiency 65, susceptibility to viral infections" in ClinVar.

Functional consequence: Loss of function — in vitro functional expression studies show the mutant protein cannot support formation of a functional ISGF3 complex upon IFN stimulation, resulting in loss of ISRE-driven transcriptional activity and failure to induce type-I-IFN-responsive interferon-stimulated genes (ISGs), while GAF (STAT1 homodimer) signaling downstream of IFN-γ remains intact.

Population frequency: Specific gnomAD constraint metrics (pLI/LOEUF) for IRF9 were not retrievable from the search tools used in this session; given that only 1–2 disease-causing families have ever been published, the pathogenic alleles themselves are expected to be essentially private/ultra-rare or absent from population databases. (Recommend direct gnomAD browser query for current o/e and LOEUF values if precise constraint metrics are required for curation.)

Somatic vs. germline: Germline only — this is a classic monogenic IEI, not a somatic/oncologic process.

Modifier genes: None specifically established; incomplete penetrance patterns are noted generally across inherited defects of type I/III IFN immunity (as discussed in reviews of IRF7/TLR3/IRF9/GATA2 severe-influenza genetics), implying as-yet-unidentified genetic or environmental modifiers.

Epigenetics/chromosomal abnormalities: No epigenetic mechanism or chromosomal-level abnormality has been reported for IMD65; it is a single-gene coding/splicing defect.

Protein structure: IRF9 is the DNA-binding subunit of ISGF3, containing: - An N-terminal DNA-binding domain (DBD) that binds the interferon-stimulated response element (ISRE). - A C-terminal IRF-association domain (IAD), structurally resolved in complex with the STAT2 coiled-coil domain (CCD) at 2.9 Å resolution (Rengachari et al., PNAS 2018). IRF9 engages the tip of the STAT2-CCD via the convex β-sandwich surface of its IAD; mutating the primary interface (IF1) abolishes STAT2 binding, while IF2/IF3 mutations do not. IRF9 has ~500-fold higher binding affinity for STAT2 than STAT1, explaining its constitutive STAT2 association even before IFN stimulation, and a recently described "molecular switch" model shows pre-formed STAT2–IRF9 complexes converting to active ISGF3 upon STAT1 recruitment after IFN stimulation (Rengachari et al. 2018; Blaszczyk et al., Nat Commun 2019).

Ontology suggestions: HGNC:6398 (IRF9); GO:0003700 (DNA-binding transcription factor activity); GO:0060333 (interferon-gamma-mediated signaling pathway, for GAF context); GO:0060337 (type I interferon-mediated signaling pathway).

Sources: ClinVar RCV000855434 · ClinVar RCV000855435 · Rengachari et al. 2018, PNAS — Structural basis of STAT2 recognition by IRF9 · Blaszczyk et al. 2019, Nat Commun — A molecular switch from STAT2-IRF9 to ISGF3 · NIH GTR — IRF9 gene

5. Environmental Information

Non-genetic contributing factors: None causal (this is a fully penetrant-for-genotype monogenic disease); environmental exposures act only as triggers that reveal the immunodeficiency.
Infectious triggers reported: Influenza A virus, RSV, parainfluenza virus, adenovirus, SARS-CoV-2, HSV-1, and VZV (both wild-type and vaccine strain). No bacterial, fungal, or parasitic triggers are specifically documented as primary drivers, though septic shock (potentially with secondary bacterial superinfection) has been listed as a clinical feature in OMIM.
Iatrogenic/vaccine exposure: Live-attenuated viral vaccines (yellow fever 17D, VZV vaccine, MMR) are a well-documented "environmental" precipitant of severe/fatal disease in this and related ISGF3-pathway deficiencies (also seen in STAT2 and IFNAR1 deficiency), underscoring why these vaccines are specifically contraindicated in this population.
Lifestyle factors: None specifically implicated; this is a pediatric-onset primary immunodeficiency, not a lifestyle-modulated disease.

Sources: Duncan et al. 2022, JACI · Hernandez et al. 2018, JEM

6. Mechanism / Pathophysiology

Core molecular pathway (causal chain):

Trigger: Viral infection → viral RNA/DNA sensing by pattern-recognition receptors (TLR3, RIG-I/MDA5) → production of type I (IFN-α/β) and type III (IFN-λ) interferons by infected cells and plasmacytoid dendritic cells.
Receptor engagement: IFN-α/β bind IFNAR1/IFNAR2; IFN-λ binds IFNLR1/IL10RB.
JAK-STAT activation: Receptor engagement activates JAK1/TYK2, which phosphorylate STAT1 and STAT2.
ISGF3 assembly (normal): Phosphorylated STAT1–STAT2 heterodimer associates with IRF9 to form the heterotrimeric ISGF3 complex. IRF9 provides the DNA-binding specificity, targeting ISGF3 to interferon-stimulated response elements (ISREs) in ISG promoters.
ISG transcription (normal): ISGF3 drives transcription of hundreds of interferon-stimulated genes establishing a cell-intrinsic antiviral state (restriction of viral replication, apoptosis of infected cells, amplification loops via IRF7).
Defect in IRF9 deficiency: Loss-of-function IRF9 variants prevent ISGF3 complex formation entirely. Patient cells can still form GAF (STAT1 homodimers, IFN-γ pathway) but cannot activate ISGF3 trimers in response to type I IFN — resulting in global failure of type I/III-IFN-driven ISG induction.
Downstream consequence: Unrestricted viral replication is observed in patient-derived cells for influenza A virus, parainfluenza virus, and RSV in vitro — a phenotype rescued by reintroducing wild-type IRF9 — demonstrating the ISGF3 pathway is essential (non-redundant) for controlling these respiratory viruses in human airway/epithelial contexts.
Paradoxical hyperinflammation branch: Even without a functional ISGF3, some IFNAR signaling persists (via GAF or residual signaling), but because ISGF3 normally also induces the negative-feedback regulator USP18 (which dampens JAK-STAT signaling), IRF9 (and STAT2) deficiency results in abnormally prolonged IFNAR signaling that shifts toward a sustained, IFN-γ-like transcriptional output. This aberrant, unchecked inflammatory signaling is proposed as the mechanism underlying the hyperinflammation/HLH phenotype seen in some patients — i.e., failure of negative feedback, not excess ISGF3 activity, drives immune dysregulation.

Cell types involved: Airway/pulmonary epithelial cells (site of respiratory viral replication and IFN response failure — modeled using iPSC-derived pulmonary epithelial cells in comparable IRF7/TLR3 studies), plasmacytoid dendritic cells, fibroblasts (used as the standard patient-cell model for functional IFN-response testing), and lymphocytes (B and T cell abnormalities noted clinically).

Suggested GO terms: - GO:0060337 – type I interferon-mediated signaling pathway (impaired) - GO:0002606 – regulation of dendritic cell antigen processing/presentation (context: pDC IFN production) - GO:0009615 – response to virus - GO:0039528 – cytoplasmic pattern recognition receptor signaling pathway (upstream sensing) - GO:0060333 – interferon-gamma-mediated signaling pathway (intact/compensatory GAF pathway)

Suggested CL terms: - CL:0002563 – respiratory basal cell / CL:0002370 – respiratory epithelial cell (site of infection) - CL:0000784 – plasmacytoid dendritic cell (IFN-α/β source) - CL:0000542 – lymphocyte (lymphopenia)

Molecular/biochemical abnormality: Complete or near-complete loss of ISGF3 DNA-binding/transcriptional activity at ISREs; GAF/STAT1-homodimer activity is preserved, distinguishing IRF9 deficiency mechanistically from STAT1 deficiency (which would ablate both ISGF3 and GAF pathways).

Omics/advanced technologies: No transcriptomic (RNA-seq/GEO), proteomic, or single-cell datasets specific to IRF9-deficient patient tissue were identified in this search; functional characterization to date has relied on classical reporter assays (ISRE-luciferase), EMSA/DNA-binding assays, phospho-flow/immunoblot for STAT1/STAT2 phosphorylation, and viral-challenge assays in patient-derived fibroblasts and complementation (wild-type IRF9 rescue) experiments.

Sources: Hernandez et al. 2018, JEM · Duncan et al. 2022, JACI · Kimura et al. 1996, original Irf9(-/-) mouse study, cited via ScienceDirect Topics IRF9 overview · Blaszczyk et al. 2019, Nat Commun

7. Anatomical Structures Affected

Primary organ: Respiratory system (lungs) — the dominant clinical target, with pneumonia/pneumonitis as the recurring presenting feature across all reported patients (influenza pneumonitis, VZV pneumonitis, COVID-19).
Secondary/complication-level involvement:
Airways: bronchiectasis (structural, likely post-infectious/inflammatory sequela) — UBERON:0002185 (bronchus), UBERON:0002048 (lung).
Nervous system: encephalitis susceptibility (HSV-1), neurological impairment as sequela of severe systemic infection — UBERON:0000955 (brain).
Hematologic/immune system: lymphopenia, hypogammaglobulinemia, HLH-associated macrophage activation — UBERON:0002371 (bone marrow), UBERON:0002106 (spleen), UBERON:0000029 (lymph node).
Systemic: septic shock, viscerotropic disease (multi-organ, seen after yellow fever vaccine) affecting liver and other viscera — UBERON:0002107 (liver).
Tissue/cell level: Respiratory epithelium (site of unrestricted viral replication), plasmacytoid dendritic cells and lymphocytes (immune dysregulation), macrophages/histiocytes (HLH).
Subcellular level: Nucleus (site of failed ISGF3-ISRE transcriptional activation); cytoplasm (site of JAK-STAT activation and STAT2-IRF9 complex assembly prior to nuclear translocation) — GO Cellular Component: GO:0005634 (nucleus), GO:0005737 (cytoplasm).
Localization pattern: Bilateral pulmonary involvement typical of viral pneumonitis (not lateralized).

Source: Hernandez et al. 2018, JEM · Duncan et al. 2022, JACI

8. Temporal Development

Onset: Congenital defect, but clinically silent until first significant viral exposure; the index patient's first severe presentation (influenza pneumonitis) was at age 2 years; the sibling family had onset in the first year of life (multiple severe viral infections including RSV and disseminated post-vaccination VZV).
Onset pattern: Acute, episodic — each viral encounter can precipitate an acute severe illness against a baseline of apparent wellness.
Progression: Not a steadily progressive degenerative disease; rather a relapsing pattern of acute severe infectious episodes, some of which leave permanent structural/functional damage (bronchiectasis, persistent neurological impairment reported in the sibling case after prolonged ICU stays).
Disease course pattern: Episodic/relapsing, punctuated by intercurrent health; underlying immunologic defect is lifelong and static (the genetic lesion does not change), but clinical burden accumulates with each infectious/vaccine-associated event.
Duration: Chronic, lifelong immunologic defect; clinical episodes are acute but recurrent across childhood (and demonstrated into at least age 8 in the COVID-19 case).
Remission: No spontaneous "cure"; interepisode periods represent clinical quiescence, not resolution of the underlying defect. Treatment-induced resolution of acute episodes (e.g., monoclonal antibody therapy) has been documented (see Treatment).
Critical periods: Early childhood is the period of highest risk, coinciding with the height of routine live-vaccine administration (MMR, VZV, and in endemic/travel contexts, yellow fever) and highest exposure to common respiratory viruses (RSV, influenza, parainfluenza) — making early genetic diagnosis critical to avoid live-vaccine—triggered catastrophic events.

Sources: Hernandez et al. 2018, JEM · Duncan et al. 2022, JACI · PMC8609338 — COVID-19 case

9. Inheritance and Population

Epidemiology: Extremely rare — to date, the peer-reviewed literature reports only two or three unrelated kindreds worldwide (one sporadic case reported in 2018, and one consanguineous two-sibling family reported in 2022), so no formal prevalence/incidence estimate exists (essentially "ultra-rare," likely well below 1/1,000,000).
Inheritance pattern: Autosomal recessive (AR); confirmed homozygosity/compound heterozygosity in all reported cases.
Penetrance: Appears high/complete for the immunologic (ISGF3 loss-of-function) defect itself, but clinical penetrance for any single infectious phenotype is incomplete and stochastic — analogous to other monogenic causes of severe influenza pneumonitis (IRF7, TLR3, GATA2), where the disease only manifests upon specific viral exposure, and severity/expressivity varies between patients and even between infectious episodes in the same patient.
Expressivity: Variable — the index patient's dominant phenotype was severe influenza pneumonitis; the sibling family's dominant phenotypes were RSV, disseminated vaccine-strain VZV, and features of hyperinflammation/HLH — illustrating that the same genotype can manifest with different predominant viral susceptibilities and different degrees of inflammatory dysregulation.
Genetic anticipation: Not applicable (not a repeat-expansion disorder).
Germline mosaicism: Not reported.
Founder effects: None established; the two published pathogenic alleles (c.991G>A and c.577+1G>T) are private to their respective families.
Consanguinity: A documented risk factor — the sibling family with c.577+1G>T arose in a consanguineous kindred.
Carrier frequency: No population carrier-frequency data available given the extreme rarity and apparent absence of these specific alleles from large population databases (gnomAD frequency data specific to IRF9 pathogenic variants were not retrievable in this search session).
Population demographics: The COVID-19 case patient was of Algerian ancestry (French nationality); the original index patient's ancestry was not specified in available search results; specific geographic/ethnic clustering has not been established beyond these isolated reports.
Sex ratio / age distribution: Insufficient case numbers (n=3–4 patients across all published reports) to derive meaningful sex ratio or age-distribution statistics.

Sources: Hernandez et al. 2018, JEM · Duncan et al. 2022, JACI · PMC8609338

10. Diagnostics

Clinical/laboratory tests: - Standard immunologic workup: lymphocyte subset enumeration (lymphopenia reported), immunoglobulin levels (hypogammaglobulinemia reported during infection), vaccine antibody responses. - Functional interferon-response assays (the gold-standard confirmatory test): patient-derived fibroblasts or PBMCs stimulated with IFN-α2b, assessed for: - ISGF3 complex formation — EMSA/DNA-binding assays showing loss of ISGF3 trimer formation while GAF (STAT1 homodimer) formation is preserved. - ISG induction — qPCR/expression panels for canonical ISGs (e.g., MX1, ISG15, IFIT1) showing blunted induction. - Phospho-flow cytometry for pSTAT1/pSTAT2 can help localize the block relative to receptor-proximal JAK-STAT signaling. - Viral challenge/complementation assays — direct demonstration that patient cells fail to control IAV/PIV/RSV replication, rescued by wild-type IRF9 re-expression (used definitively in the index case). - Biopsy/histopathology: Not a primary diagnostic modality for this condition (no characteristic tissue histopathology reported beyond nonspecific inflammatory/HLH-type bone-marrow or lymph-node findings during acute hyperinflammatory episodes).

Genetic testing: - Recommended approach: Given the phenotypic overlap with other IEIs of type I/III interferon immunity (IRF7, STAT1, STAT2, TYK2, IFNAR1/2, TLR3, IFIH1, GATA2), a targeted primary immunodeficiency/severe viral susceptibility gene panel or whole-exome/whole-genome sequencing is the standard diagnostic route, as used in both published cases (WES in the index case; panel sequencing in the consanguineous sibling family). - Single-gene testing: Reasonable if a specific IRF9 variant is suspected from family history or panel screening. - Chromosomal microarray/karyotyping/FISH: Not indicated — this is a single-gene coding/splice-site disorder, not a copy-number or structural chromosomal disease. - Confirmatory functional testing (as above) is recommended given the WES/panel finding, since splice-site predictions (e.g., c.991G>A) benefit from functional/RNA-level confirmation.

Clinical criteria/differential diagnosis: No formal diagnostic consensus criteria exist (too rare); the practical differential diagnosis for a child presenting with unexplained severe/recurrent viral pneumonitis and/or severe reaction to live vaccines includes: STAT1 deficiency, STAT2 deficiency (IMD62), IRF7 deficiency (IMD51), TLR3 deficiency, IFNAR1/IFNAR2 deficiency, TYK2 deficiency, IFIH1 deficiency, GATA2 deficiency, and severe combined immunodeficiency (SCID) more broadly, particularly when a live-vaccine-associated catastrophic illness is the presenting event (as SCID is the more common genetic cause of such presentations, and must be excluded).

Screening: No population newborn-screening program targets IRF9 specifically; however, given the risk of catastrophic reactions to live-attenuated vaccines, genetic/immunologic screening prior to live vaccination (MMR, VZV, yellow fever) is warranted in any infant with a family history of unexplained severe/fatal reactions to viral infection or vaccination, and cascade testing of siblings in an index family is recommended (as performed in the reported sibling kindred).

Sources: Hernandez et al. 2018, JEM · Duncan et al. 2022, JACI

11. Outcome/Prognosis

Survival/mortality: Not uniformly fatal, but the disease has a documented lethal potential — one reported association is a fatal enterohemorrhagic/viscerotropic-type illness following yellow fever vaccination, and the disseminated post-vaccination VZV pneumonitis episode in the sibling family was severe/life-threatening. The index patient and the COVID-19 case patient both survived their severe infectious episodes with appropriate intensive/targeted therapy.
Life expectancy: No formal actuarial data exist given the extremely small number of published patients; prognosis appears strongly dependent on avoidance of live vaccines and prompt, aggressive management of viral infections (including early antiviral/monoclonal antibody intervention).
Morbidity/functional outcomes: Bronchiectasis (chronic structural lung disease) and persistent neurological impairment have been documented as long-term sequelae following severe infectious episodes in the sibling family, indicating that even survivors can carry significant chronic morbidity.
Complications: Pneumonia/pneumonitis, bronchiectasis, septic shock, HLH/hyperinflammation, encephalitis (HSV-1 risk), and vaccine-strain disseminated viral disease are all recognized complications.
Recovery potential: With early diagnosis, live-vaccine avoidance, and prompt treatment of acute viral episodes (including newer targeted therapies such as neutralizing monoclonal antibodies), acute episodes can resolve without further sequelae — as demonstrated in the COVID-19 case, where the patient was completely asymptomatic with an unremarkable follow-up at day 50 after monoclonal antibody treatment.
Prognostic factors: Early genetic diagnosis (enabling live-vaccine avoidance and vigilant infection management) appears to be the single most actionable prognostic factor described in the literature; no specific molecular biomarker for prognosis (beyond the underlying genotype) has been established.

Sources: PMC8609338 — Monoclonal antibody neutralization of SARS-CoV-2 in an IRF9-deficient child · Duncan et al. 2022, JACI

12. Treatment

Because IRF9 deficiency disables an endogenous antiviral signaling pathway rather than a druggable enzyme, management is centered on prevention (avoiding triggers), passive/targeted antiviral immunity, and supportive/immunomodulatory care, rather than gene-specific pharmacotherapy.

Pharmacotherapy / targeted antiviral therapy: - Neutralizing monoclonal antibodies — In the best-documented treatment success, an 8-year-old IRF9-deficient girl with SARS-CoV-2 infection and very high viral load was treated with a half-dose (600 mg total) of the casirivimab + imdevimab monoclonal antibody combination on day 2 of illness; her viremia cleared by day 4, and pneumonia was prevented entirely — demonstrating that direct viral neutralization can compensate for a complete defect in interferon-dependent intrinsic antiviral immunity. Suggested NCIT term: NCIT:C171760 (Monoclonal Antibody Therapy) / therapeutic modality = MONOCLONAL_ANTIBODY. - Interferon-lambda (peginterferon-λ) is mechanistically attractive as a potential therapeutic in some interferon-pathway defects (given its epithelial-restricted receptor distribution and lower systemic toxicity than IFN-α), and has independent evidence as an early COVID-19 antiviral in the general population; however, it would not be expected to bypass an ISGF3-complex defect like IRF9 deficiency, since IFN-λ signals through the same downstream ISGF3 machinery — its utility in this specific IEI is therefore mechanistically limited/unproven, unlike its role in other, more receptor-proximal defects.

Immunoglobulin/passive immunity: - Immunoglobulin replacement therapy (IVIG/SCIG) is a mainstay supportive strategy in PID management generally and has specifically been proposed as protective in ISGF3-pathway deficiencies, since pooled immunoglobulin from immunocompetent donors provides passive neutralizing antibody coverage against common pathogens, substituting for the patient's own impaired antiviral defense. NCIT term candidate: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent = immune globulin.

Preventive/avoidance strategy (most emphasized in the literature): - Strict avoidance of live-attenuated viral vaccines (yellow fever 17D, VZV vaccine, MMR) is the single most repeatedly emphasized management recommendation, given documented severe/fatal reactions in this and related ISGF3-pathway deficiencies (STAT2, IFNAR1/2). - Use of inactivated/killed vaccines where possible for routine immunization.

Supportive care: - Aggressive supportive management of acute severe viral pneumonitis episodes (mechanical ventilation, ICU-level care), as required in the index influenza case. - Management of HLH/hyperinflammatory episodes would follow standard HLH-directed immunomodulatory protocols (e.g., corticosteroids, IL-1/IL-6 pathway-directed therapy where clinically indicated), though no IRF9-deficiency-specific HLH treatment trial data exist.

Experimental/investigational: - No gene therapy, gene editing, or hematopoietic stem cell transplantation approach has been reported specifically for IRF9 deficiency in the literature surveyed (unlike some other severe IEIs where HSCT is curative, IRF9 deficiency's defect is not primarily hematopoietic-cell-intrinsic in a way that clearly predicts HSCT benefit, and no such case has been published). - No disease-specific registered clinical trials (ClinicalTrials.gov) were identified for IRF9 deficiency specifically.

Treatment outcomes: The single best-documented outcome is the COVID-19 case, in which monoclonal antibody therapy prevented pneumonia and led to full recovery with no residual symptoms at 50-day follow-up — supporting monoclonal antibody-based passive immunotherapy as a rational, evidence-based intervention for this genotype during specific viral infections for which such antibodies are available.

Personalized/genotype-guided approach: Because the defect is precisely characterized at the molecular level (loss of ISGF3 formation, intact GAF), therapy can be rationally targeted to bypass rather than restore the defective pathway — i.e., preferring therapies that act independently of ISGF3 (direct viral neutralization via monoclonal antibodies, passive immunoglobulin) over therapies that would require an intact ISGF3 response to be effective (e.g., IFN-α/β or IFN-λ administration alone, which would be expected to have blunted efficacy).

Sources: PMC8609338 — Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child · Duncan et al. 2022, JACI

13. Prevention

Primary prevention: Not possible at the population level (no environmental risk factor to modify); at the individual/family level, genetic counseling and carrier testing in families with a known pathogenic IRF9 allele, plus avoidance of live-attenuated vaccines in confirmed or at-risk individuals, constitute the primary preventive strategy.
Secondary prevention (early detection): Prompt genetic diagnosis following a first severe/atypical viral infection episode enables early institution of protective measures (vaccine avoidance, close infection monitoring, early antiviral/monoclonal antibody treatment access) before a second, potentially fatal, event occurs — as illustrated by the index-to-sibling diagnostic cascade in the second reported family.
Genetic counseling: Essential in any family with a confirmed proband, given autosomal recessive inheritance (25% recurrence risk for future siblings) and demonstrated consanguinity risk; prenatal or preimplantation genetic testing could be considered in informed families given the demonstrated risk of fatal outcomes.
Screening for at-risk relatives: Cascade genetic screening of siblings (as performed in the consanguineous family) allows pre-symptomatic identification and vaccine-avoidance counseling before a sentinel catastrophic event.
Immunization strategy: Substituting inactivated vaccines for all live-vaccine equivalents in the routine immunization schedule where such alternatives exist, and case-by-case risk-benefit discussion (with likely deferral/avoidance) for vaccines with no inactivated alternative (e.g., yellow fever, where travel to endemic areas would need individualized risk mitigation such as avoidance or reliance on non-vaccine protective measures).
Prophylaxis: Regular immunoglobulin replacement has been suggested as a prophylactic strategy providing passive antiviral antibody coverage in ISGF3-pathway-deficient patients.
Public health relevance: As an ultra-rare monogenic condition, this disease has no population-level public-health intervention; its main public-health relevance is as a genetic explanatory model informing broader vaccine-safety monitoring for rare severe/fatal live-vaccine reactions in children, prompting genetic workup in such sentinel cases.

Sources: Duncan et al. 2022, JACI · Hernandez et al. 2018, JEM

14. Other Species / Natural Disease

Taxonomy: No naturally occurring IRF9-deficiency disease has been reported in non-human species (companion animals or wildlife) in the sources surveyed.
Orthologous gene: Irf9 is highly conserved across mammals; the mouse ortholog (Irf9, historically Isgf3g, protein p48) is the basis of the principal animal model (see Section 15). NCBI Gene IDs: human IRF9 = 10379; mouse Irf9 ortholog exists in MGI (specific ID not retrieved in this session).
Comparative biology: The IRF9-STAT1-STAT2 ISGF3 axis is deeply conserved across vertebrates, underlying its fundamental role in antiviral immunity; a recent (2024) preprint reports identification of avian IRF3 and IRF9 orthologs, reflecting ongoing interest in evolutionary conservation of this pathway across the IRF family, though this is basic comparative genomics rather than a disease model.
Zoonotic potential/cross-species susceptibility: Not applicable — this is a human genetic immunodeficiency, not an infectious/zoonotic disease itself.

Sources: Avian IRF3/IRF9 preprint, bioRxiv 2024 · general IRF9 literature above

15. Model Organisms

Primary model: Irf9-knockout (formerly Isgf3g/"p48"-null) mice (Kimura et al., 1996 — the original characterization).

Model type: Mammalian, germline gene-knockout (constitutive, whole-organism).
Key phenotype: Irf9⁻/⁻ mice fail to survive viral challenge; in Irf9⁻/⁻-derived embryonic fibroblasts (EFs) and peritoneal macrophages, IFN-α– or IFN-γ–induced antiviral states are abolished or dramatically impaired against multiple virus classes tested (encephalomyocarditis virus [EMCV], vesicular stomatitis virus [VSV], herpes simplex virus [HSV]). ISGF3-like DNA-binding activity, present in IFN-γ–stimulated wild-type fibroblasts, is absent in Irf9⁻/⁻ fibroblasts, and IFN-α–induced ISG expression is severely blunted.
Fidelity to human disease: This model recapitulates the core human mechanistic defect (loss of ISGF3-dependent antiviral gene induction and consequent uncontrolled viral replication) with high fidelity at the molecular/cellular level; however, the mouse constitutive-knockout phenotype (susceptibility across at least three virus classes, with lethality on challenge) is notably more severe/broadly susceptible than the surviving human patients, who — despite comparable ISGF3 loss — have survived to school age with targeted interventions, illustrating a translational gap likely explained by differences in pathogen exposure, redundant human host defenses (e.g., passive/adaptive immunity, medical intervention), and species-specific differences in interferon biology.
Limitations: The constitutive knockout does not model the episodic/vaccine-triggered clinical pattern seen in humans, nor the paradoxical hyperinflammatory/HLH phenotype now recognized in human STAT2/IRF9 deficiency (which depends on subtler negative-feedback dysregulation, e.g., via USP18, that may not be fully captured in acute lethal-challenge knockout studies).
Research applications: The Irf9-null mouse remains the standard tool for dissecting ISGF3-dependent versus ISGF3-independent (e.g., STAT2/IRF9-only, or GAF-mediated) antiviral and immunoregulatory pathways, and has also been used to study IRF9's role in preventing CD8+ T-cell exhaustion during chronic LCMV infection (an extrinsic, non-cell-autonomous immunoregulatory role for IRF9 beyond classical antiviral ISG induction) and in intestinal inflammation (noncanonical IRF9 effects reported independent of type I/III interferon signaling).
Cellular/in vitro models: Human patient-derived primary fibroblasts and PBMCs (used in both published human case reports) remain the principal disease-relevant cellular models, with viral-challenge complementation (wild-type IRF9 re-expression rescuing antiviral control) serving as the functional proof of causality in humans, analogous in logic to the mouse knockout/rescue paradigm.
Resources: MGI (Mouse Genome Informatics) for Irf9 allele records; no zebrafish, Drosophila, or C. elegans orthologous disease models were identified in this search (IRF-family transcription factors of this type are vertebrate-specific innovations, limiting invertebrate modeling utility).

Sources: ScienceDirect Topics — IRF9 overview, summarizing Kimura et al. 1996 · IRF9 Prevents CD8+ T Cell Exhaustion, J Virol 2017 / PMC5660491 · Noncanonical Effects of IRF9 in Intestinal Inflammation, PubMed 25918247

Summary of Key Citations

Hernandez N, et al. "Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency." J Exp Med. 2018;215(10):2567–2585. PMID: 30143481. https://rupress.org/jem/article/215/10/2567/120233/
Duncan CJA, et al. "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency." J Allergy Clin Immunol. 2022. PMID: 35182547. https://www.jacionline.org/article/S0091-6749(22)00185-3/fulltext
"Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child." PMC8609338. https://pmc.ncbi.nlm.nih.gov/articles/PMC8609338/
OMIM #618648 — IMMUNODEFICIENCY 65, SUSCEPTIBILITY TO VIRAL INFECTIONS. https://www.omim.org/entry/618648
OMIM *147574 — INTERFERON REGULATORY FACTOR 9; IRF9. https://omim.org/entry/147574
Rengachari S, et al. "Structural basis of STAT2 recognition by IRF9 reveals molecular insights into ISGF3 function." PNAS. 2018. https://www.pnas.org/doi/10.1073/pnas.1718426115
Blaszczyk K, et al. "A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription." Nat Commun. 2019. PMID: (PMC6606597). https://www.nature.com/articles/s41467-019-10970-y
"Human genetics of life-threatening influenza pneumonitis." Hum Genet. 2019. PMC7094886. https://pmc.ncbi.nlm.nih.gov/articles/PMC7094886
ClinVar RCV000855434 (c.577+1G>T) and RCV000855435 (c.991G>A/p.Asp331Asn), NCBI. https://www.ncbi.nlm.nih.gov/clinvar/
IRF9 gene records — GeneCards, NCBI GTR. https://www.genecards.org/cgi-bin/carddisp.pl?gene=IRF9 · https://www.ncbi.nlm.nih.gov/gtr/genes/10379/

Note on data gaps: This is one of the rarest inborn errors of immunity in the literature (only ~2 published kindreds, ~3–4 total patients as of this writing), so several requested data points — formal prevalence/incidence, gnomAD constraint metrics, QoL instrument scores, and any animal-model-independent transcriptomic/proteomic datasets — are simply not available in the primary literature and should be flagged as "not yet documented" (NOT_YET_DOCUMENTED) rather than estimated when this report is used to populate structured knowledge-base fields (e.g., PrevalenceClassEnum). One search result linking IRF9 to "alacrima, achalasia, and impaired intellectual development syndrome" (Triple-A syndrome) is flagged as almost certainly a gene-database cross-contamination artifact (that syndrome is caused by AAAS, not IRF9) and should not be incorporated into curation.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	8
Resolved	8
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	8
On topic	4
Off topic	0

All extracted references resolved successfully.

Immunodeficiency 65 (IRF9 Deficiency)

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Animal Models

Source YAML

References & Deep Research

Deep Research

Immunodeficiency 65 (IRF9 Deficiency): Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

Infectious phenotypes

Inflammatory/immune dysregulation phenotypes

Laboratory abnormalities

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Citations

Reference Validation